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A B S T R A C T   
The Molecule Interacting with CasL 1 (MICAL1) monooxygenase has emerged as an important regulator of 
cytoskeleton organization via actin oxidation. Although filamentous actin (F-actin) increases MICAL1 mono-
oxygenase activity, hydrogen peroxide (H2O2) is also generated in the absence of F-actin, suggesting that 
diffusible H2O2 might have additional functions. MICAL1 gene disruption by CRISPR/Cas9 in MDA MB 231 
human breast cancer cells knocked out (KO) protein expression, which affected F-actin organization, cell size and 
motility. Transcriptomic profiling revealed that MICAL1 deletion significantly affected the expression of over 700 
genes, with the majority being reduced in their expression levels. In addition, the absolute magnitudes of reduced 
gene expression were significantly greater than the magnitudes of increased gene expression. Gene set enrich-
ment analysis (GSEA) identified receptor regulator activity as the most significant negatively enriched molecular 
function gene set. The prominent influence exerted by MICAL1 on F-actin structures was also associated with 
changes in the expression of several serum-response factor (SRF) regulated genes in KO cells. Moreover, MICAL1 
disruption attenuated breast cancer tumour growth in vivo. Elevated MICAL1 gene expression was observed in 
invasive breast cancer samples from human patients relative to normal tissue, while MICAL1 amplification or 
point mutations were associated with reduced progression free survival. Collectively, these results demonstrate 
that MICAL1 gene disruption altered cytoskeleton organization, cell morphology and migration, gene expression, 
and impaired tumour growth in an orthotopic in vivo breast cancer model, suggesting that pharmacological 
MICAL1 inhibition could have therapeutic benefits for cancer patients.   
1. Introduction 
The metastatic spread of cancer cells from primary tumours to 
distant sites is the deadliest aspect of the disease, estimated to contribute 
to ~90 % of solid cancer deaths [1]. The development of secondary 
tumours is often life threatening due to the loss of function of critically 
important tissues and organs, and because of limited effective treatment 
options following cancer cell dissemination. While the most efficacious 
cancer therapies are aided by early detection and removal of primary 
tumours before they become metastatic, many aggressive cancers such 
as breast, melanoma, pancreatic and lung [2–5] are often able to invade 
into lymphatic and blood vasculature systems before primary tumours 
are detected. Although conventional chemotherapies do not distinguish 
between tumour and healthy normal cells, resulting in toxic side effects, 
cancer selectivity may be achieved by targeting proteins that have 
prominent roles in the growth and progression of tumours, including 
proteins that contribute to cancer cell invasion and metastasis. 
Metastasis is a multi-step process driven by the dynamic reorgani-
zation of the actin-myosin cytoskeleton [6]. Given that the cytoskeleton 
has essential roles in many fundamental processes [7], therapeutic drugs 
that directly target microfilaments have limited clinical utility due to 
their adverse impact on normal cell health. Alterations in the activity of 
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proteins that regulate cytoskeleton organization can influence the ad-
hesive and invasive properties of tumour cells, as well as their prolif-
eration and survival [8]. As a result, considerable effort has been 
focussed on identifying cytoskeleton regulators that are co-opted, 
mutated or differentially expressed in tumours because of their poten-
tial as cancer therapeutic targets [9]. 
Extracellular signals initiate the recruitment of protein complexes 
that catalyze the polymerization of actin monomers into filaments at cell 
leading edges [10]. The same extracellular signals trigger processes that 
contribute to F-actin severing or depolymerization, separated spatially 
and/or temporally from the actin polymerization machinery to enable 
dynamic reorganization of cytoskeleton structures. There is a growing 
body of evidence demonstrating that reactive oxygen species (ROS) act 
as important intermediary signalling molecules that regulate cellular 
pathways and processes that play prominent roles in cancer. ROS, such 
as hydrogen peroxide (H2O2), oxidize amino acid side chain thiols on 
proteins, producing oxidative intermediates and disulphide modifica-
tions [11]. These post-translational modifications have dramatic con-
sequences on thiol structure that can result in changes in protein activity 
and localization [12]. ROS have been found elevated in many cancer 
types and can activate several signal transduction pathways that pro-
mote cellular growth and proliferation [13] [14]. In particular, there 
appears to be a close relationship between ROS generation and remod-
elling of the actin cytoskeleton to promote cancer motility and invasion 
[15,16]. Several known actin-binding proteins have previously been 
identified as being redox sensitive [17], and actin itself contains a 
number of reactive methionine residues that are subject to 
post-translational thiol modifications [18]. We previously discovered 
that H2O2 generation at the leading edge of migrating cells promotes the 
motility of invasive breast cancer cells through the oxidation, and sub-
sequent inhibition, of the actin-severing protein cofilin1 [17]. Cofilin1 
oxidation on cysteines 139 and 147 reduced its actin-binding and 
severing activities, while expression of oxidation-resistant cofilin1 mu-
tants in cells inhibited cell spreading, and adhesion, and reduced the 
directionality of random migration relative to the expression of 
wild-type cofilin1. An outstanding question that emerged from those 
studies was the source of H2O2 at the leading edge of polarized migrating 
cells. 
A significant cellular source of ROS production comes from the 
NADPH/DUOX oxidases (NOX/DUOX) and the recently described 
MICAL enzymes. NOX/DUOXs are a family of transmembrane flavo-
proteins that generate high levels of superoxide (or H2O2 depending on 
the isoform), and play diverse roles in cell physiology [19]. The cyto-
plasmic Molecule Interacting with CasL (MICAL) family proteins are 
flavo-monooxygenases that either directly oxidize bound proteins such 
as actin, or generate diffusible H2O2 that can oxidize nearby proteins 
such as collapsin response mediator protein-2 (CRMP2) [20]. The most 
well-defined function of the archetypal family member MICAL1 is 
F-actin depolymerization [21], which has important cell-specific roles 
including axon guidance and synapse development in neurons [22], and 
macrophage function [18]. MICAL1 regulation of F-actin structures is 
also important for successful cytokinesis in a variety of cell types [23]. 
To identify the H2O2 generating enzyme that influenced MDA MB 
231 triple negative human breast cancer cell migration, we used 
CRISPR/Cas9 to knockout (KO) the MICAL1 gene that we had deter-
mined to be the most highly expressed non-nuclear NOX/DUOX or 
MICAL family protein. We found that MICAL1 KO had significant effects 
on F-actin organization, which were associated with increased two- 
dimensional cell areas and three-dimensional cell volumes without 
significantly affecting cell shape. Consistent with MICAL1 regulating 
cytoskeleton structures, the random migration of MICAL1 KO cells was 
less directional, resulting in reduced forward distances being travelled 
over time. In addition, MICAL1 KO cells closed gaps less efficiently in 
scratch wound healing assays. Gene expression analysis by RNA 
sequencing revealed that over 700 genes were significantly altered in 
MICAL1 KO cells relative to control cells, with more genes being reduced 
in their expression compared to the number that were increased. In 
addition, the absolute magnitudes of reduced gene expression were 
significantly greater than the magnitudes of increased gene expression, 
and transcription factor target gene sets were negatively enriched. A 
gene set associated with the regulation of receptor activity was signifi-
cantly negatively enriched in MICAL1 KO cells, as were several genes 
regulated by the actin-responsive serum-response factor (SRF) tran-
scription factor. Growth of MICAL1 KO cells as orthotopic xenograft 
tumours in immunocompromised mice was significantly reduced rela-
tive to control cells. A role for MICAL1 in human breast cancer was 
supported by results from publicly available databases, which revealed 
increased MICAL1 expression in invasive breast cancers relative to 
normal mammary tissue and an association of MICAL1 gene amplifica-
tion or mutation with significantly reduced progression free survival. 
Taken together, these results demonstrate that MICAL1 is an important 
regulator of actin cytoskeleton organization, cell morphology and 
motility, gene transcription, and in vivo tumour growth of human breast 
cancer cells. The findings of this study suggest that MICAL1 is a potential 
drug target for breast cancer chemotherapy, future research will deter-
mine if other cancer types could also benefit from MICAL1 inhibition. 
2. Materials and methods 
2.1. Cell culture 
MDA MB 231 and HEK293T cells were grown in DMEM (Sigma) 
supplemented with 10 % fetal bovine serum (FBS), 10 U/ml penicillin 
and 10 μg/ml streptomycin (Gibco). Cell line authentication was vali-
dated using STR profiling by the Cancer Research UK Beatson Institute 
Molecular Services, and cells were routinely tested for mycoplasma 
contamination. CRISPR/Cas9-mediated MICAL1 knockouts were 
generated using the lentiCRISPR plasmid as previously described [24]. 
Target sequences for MICAL1 are shown in Fig. S1A. 
2.2. RNA isolation and qPCR 
RNA and cDNA were isolated and prepared from MDA MB 231 cells 
as previously described [25]. Briefly, 5 x 105 cells were seeded onto 6 cm 
culture dishes and grown for 48 h. Cells were washed in PBS, and RNA 
was isolated using RNAeasy kits (Qiagen) according to the manufac-
turer’s instructions. For RT-PCR reactions, cDNA was prepared using 
Quantitect Reverse Transcription kits (Qiagen). For gene expression 
analysis of NOX1-5, DUOX1-2 and MICAL1 (Fig. 1A), qPCR reactions 
were performed using QuantiTect primers (Qiagen) as follows; NOX1 
(QT00025585), NOX2 (QT00029533), NOX3 (QT00044737), NOX4 
(QT00057498), NOX5 (QT00021924), DUOX1 (QT00038346), DUOX2 
(QT00012236), MICAL1 (QT00008421). For validation of targets from 
RNAseq analysis (Fig. 4E), qPCR reactions were performed using KiCq-
Start® SYBR® Green kits (Sigma), with the following primer pairs; 
RHOB (5′-aaattttctctgcacctctg, 5′-gctcaccattttgtcatttg), SDC2 (5′-aaagt-
cacctgaagaaactg, 5′-agactgtctgagtgtttctc), CYR61 (5′-ttgattgcagttg-
gaaaagg, 5′-gccttgtaaagggttgtatag). In all experiments, melting curves 
were generated to ensure the presence of a single PCR product for each 
primer. Gene expression data were calculated using ΔCt and normalized 
against GAPDH. 
2.3. Immunoblotting 
Immunoblots were performed as previously described [26]. Cells 
were washed thoroughly with ice cold PBS and lysed in buffer con-
taining 1 % SDS, 50 mM Tris pH 7.5. Lysates were clarified at 13,000 
rpm for 15 min and protein content measured using a BCA assay. Lysates 
(10 μg) were resolved on 4–12 % NuPAGE Bis-Tris gel and transferred to 
nitrocellulose membranes. Membranes were incubated with the 
following primary antibodies; anti-MICAL1 (Proteintech, 14818-1-AP), 
GAPDH (Millipore, MAB374), Cas9 (Diagenode, C15200203) and 
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secondary antibodies; IRDye® 680RD and 800CW (LiCor). Proteins were 
visualized by infrared imaging using LiCor Odyssey CLx. 
2.4. Fluorescence microscopy 
MDA MB 231 cells were grown on glass cover slips in 24 well plates. 
The next day, cell medium was removed, and cells were fixed with 4 % 
paraformaldehyde/PBS for 15 min at room temperature, then washed 
three times in PBS. For immunofluorescence, cells were permeabilized 
with 0.5 % Triton X-100/PBS for 5 min and washed with PBS. Cells were 
blocked with 1 % BSA/PBS for 30 min before being incubated with Alexa 
Fluor 488-conjugated phalloidin (Thermo Fisher, A12379). Images were 
taken using a Zeiss 710 upright confocal microscope. 
2.5. Cell areas and diameters 
Cell areas were analyzed as described previously [27]. Cells were 
fixed with 4 % paraformaldehyde/PBS in 96 well black plates and per-
meabilized with 0.5 % Triton X-100/PBS for 5 min at room temperature. 
After blocking with 1 % BSA/PBS, cells were stained with Cellomics® 
Fig. 1. MICAL1 gene disruption affects cell size and actin organization. A. Expression of NOX1-5, DUOX1&2 and MICAL1 in MDA MB 231 cells as determined by RT- 
PCR. Means ± SD relative to mean expression of NOX1, n = 3 independent replicates. B. Validation of MICAL1 knockout in MDA MB 231 cells by Western blot 
analysis of untreated cells (− ), non-targeting control (NTC) and 4 independent sgRNA (2–5) targeted isolates C. Confocal microscopy images of phalloidin staining of 
fixed NTC or MICAL1 KO cells. Scale bars = 20 μm. D. MDA MB 231 NTC and MICAL1 KO cell areas (μm2) were measured by high content imaging. Means ± SD, n =
120 individual cells imaged in 3 independent replicate experiments, indicated by the differing shading of each symbol. **** = p < 0.0001 (one-way ANOVA with 
post-hoc Dunnett’s multiple comparisons test). E. Mean diameters (μm) of suspended NTC and MICAL1 KO cells. Means ± SD, n = 19 (NTC), 20 (KO1) and 18 (KO2) 
independent determinations, with >5000 cells counted per replicate. **** = p < 0.0001 (one-way ANOVA with post-hoc Dunnett’s multiple comparisons test) F. Left 
panels; TIRF images of phalloidin stained NTC and MICAL1 KO MDA MB 231 cells. Scale bars = 20 μm. Right panel; F-actin anisotropy of phalloidin stained NTC and 
MICAL1 KO MDA MB 231 cells. Means ± SD, n = 50 individual cells. **** = p < 0.0001, * = p < 0.05, (one-way ANOVA with post-hoc Dunnett’s multiple com-
parisons test t-test relative to NTC condition). 
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Whole Cell Stain (Thermo Fisher Scientific, 8303401) for 30 min and 
0.15 μg/ml DAPI (Sigma, D9542) for 20 min. Images were taken using 
an Operetta high-content imaging system, and data analyzed using the 
Columbus™ Analysis System (PerkinElmer). Mean diameter measure-
ments were determined using a CASY® Cell Counter as described in 
Ref. [27]. For each independent mean diameter determination, >5000 
cells were counted per replicate determination. 
2.6. TIRF microscopy and F-actin anisotropy 
Total internal reflectance (TIRF) images of phalloidin stained cells 
were taken using a Diskovery Multi-Model Imaging System (Quorum). 
Samples were prepared as described for fluorescence microscopy. 
Analysis of F-actin anisotropy was performed using the image J plugin 
FibrilTool [28]. 
2.7. Cell motility and morphology 
MDA MB 231 cells were seeded at 1500 cells per well in 96 well 
ImageLock plates (Sartorius) and left for 24 h. Cells were treated with 
Incucyte Nuclight Rapid Red Dye (Sartorius), according to the manu-
facturer’s protocol, and imaged every 10 min for 18 h in an IncuCyte S3 
instrument (Sartorius) using a 10X objective. Time lapse images were 
imported into ImageJ2, and tracking files were generated using Track-
Mate as per the developer’s protocol. Manual cell masking of eighth 
hour time lapse images (08h00 m) was completed in ImageJ to segment 
individual cell bodies, which were measured for size and shape using 
CellProfiler analysis software. 
2.8. siRNA transfection 
BT549 and SUM149PT cells were grown at 5 x 104 cells per well in 6 
well plates. After 24 h, cells were transfected with siRNA using Lip-
ofectamine RNAiMax (ThermoFisher), according to the manufacturer’s 
instructions. ON-TARGETplus NTC and MICAL1 siRNAs were purchased 
from Dharmacon and used at 20 nM. After transfection, cells were 
incubated for 48 h before being washed, trypsinized, and seeded at 1 x 
103 cells per well in Essen Bioscience ImageLock 96 well plates. Cells 
were imaged as described in the Cell Motility methods section. 
2.9. Scratch wound migration assay 
Cell migration was measured using the IncuCyte® S3 Live-Cell Sys-
tem [29]. Cells were seeded at 2 x 104 per well of Essen Bioscience 
ImageLock 96 well plates such that they formed confluent monolayers 
the next day. A wound was created using the IncuCyte® Woundmaker 
Tool. Cells were washed 3 times in full medium, then placed into the 
IncuCyte® S3 chamber. Brightfield images of the wells were taken every 
2 h for a total of 48 h and wound width measured using the IncuCyte® 
S3 software. 
2.10. RNA-sequencing and analysis 
RNA-sequencing and analysis was performed as previously described 
[25]. RNA was isolated as described above for RT-PCR analysis, with the 
addition of on-column DNase digestion. 
2.11. Mouse breast cancer model 
Animal studies were performed in accordance with the UK Home 
Office regulations, in line with the Animals (Scientific Procedures) Act 
1986, and approved by the University of Glasgow College of Medicine, 
Veterinary and Life Sciences Research Ethics Committee. All experi-
ments were carried out under UK Home Office project licence authority 
(70/8645; held by KB) in dedicated barriered animal care facilities. 
MDA MB 231 control or MICAL KO cells (1x106) in 50 μl of 50 % 
Matrigel were transplanted to the inguinal (#4) mammary fat pads of 9 
week CD1nu/nu immunocompromised female mice (Charles River Ltd, 
UK). Tumours were calliper measured and volumes calculated using the 
formula (Length x width2)/2. Mice were euthanized when tumours 
reached 10 mm in diameter or after 86 days. 
3. Results 
3.1. MICAL1 disruption in MDA MB 231 cells 
To identify potential sources of H2O2 that could facilitate cell 
motility, we profiled the expression of non-nuclear ROS generating en-
zymes by RT-PCR and found that the expression of MICAL1 was greater 
than NOX1-5 and DUOX1-2 enzymes in MDA MB 231 cells (Fig. 1A). 
CRISPR/Cas9 technology was used with single guide RNAs (sgRNAs) 
that were designed to target exon 2 or exon 3 of the MICAL1 gene to 
generate MICAL1 knockout (KO) MDA MB 231 cell lines (Fig. S1A). 
Polyclonal expansion of lentivirus-transduced CRISPR/Cas9 KO cells 
avoided the risk of selecting individual subcellular populations from 
monoclonal expansions. As shown in Fig. 1B and Fig. S1B, MICAL1 was 
successfully knocked-out with multiple sgRNAs that targeted exon 2 or 
exon 3, while the non-targeting control (NTC) construct did not affect 
MICAL1 protein despite Cas9 expression. For subsequent studies, we 
selected MICAL1 KO cell lines generated with the exon 3 targeted 
sgRNA3 (KO1) and the exon 2 targeted sgRNA4 (KO2). 
3.2. MICAL1 knockouts alter the size of MDA MB 231 cells 
The most well-defined function of MICAL1 is the oxidation of actin 
on Met44 and Met47, resulting in actin depolymerization and alterations 
to the organization of the actin cytoskeleton [21]. Using MDA MB 231 
breast cancer MICAL1 KO cells, we assessed whether MICAL1 loss 
altered cellular morphological properties that could arise from changes 
in cytoskeleton organization. Confocal microscope images of 
phalloidin-stained MDA MB 231 cells showed obvious changes in cell 
size (Fig. 1C). Quantification of mean two-dimensional areas of adherent 
cells (Fig. 1D and Fig. S2) or mean diameter of cells in suspension 
(Fig. 1E) revealed that MICAL1 KO cells were significantly larger. 
Consistent with these changes, specific morphological parameters that 
are functionally related to altered cell size were significantly different in 
both KO1 and KO2 cells relative to the NTC control cells, including 
maximum (Fig. S3A), median (Fig. S3B) and mean radius (Fig. S3C), 
perimeter (Fig. S3D), and major (Fig. S3E) and minor axis lengths 
(Fig. S3F). In contrast, unitless relative parameters that relate to cell 
shape were unaffected by MICAL1 knockout, including cell eccentricity 
(Fig. S3G), area shape extent (Fig. S3H) and area shape form factor 
(Fig. S3I). To quantify differences in F-actin organization, total internal 
reflectance microscopy (TIRF) was used to reveal F-actin structures 
along a ~0.2 μm plane at cell-substrate interfaces (Fig. 1F, left panels), 
to eliminate possible effects of cell height differences. F-actin structures 
can be described as anisotropic if the organization is directionally 
biased, or isotropic when filament distribution is uniform in all di-
rections. TIRF images were analyzed for F-actin anisotropy [28], which 
revealed that MDA MB 231 MICAL1 KO cells had significantly increased 
F-actin anisotropy relative to NTC cells (Fig. 1F, right panel). These 
results demonstrate that disruption of MICAL1 in MDA MB 231 cells led 
to cell size changes associated with alterations to the organization of the 
actin cytoskeleton. 
3.3. MICAL1 disruption affects cell motility 
We previously determined that MDA MB 231 cells selected on their 
ability to pass through 3 μm diameter micropores were more motile that 
unselected parental cells, which was associated with decreased F-actin 
anisotropy and smaller cell size [27]. Given that MICAL1 KO resulted in 
increased cell size and F-actin anisotropy (Fig. 1), we sought to 
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determine whether MICAL1 deletion would also affect cell motility. The 
random migration of individual NTC and MICAL1 KO cells were tracked 
over 18 h. As shown in Spider cell track plots in Fig. 2A, MICAL1 KO 
markedly reduced cell motility. Quantification of these individual cell 
tracks revealed that MICAL1 deletion resulted in significantly ≥16 % 
reduced track displacement (Fig. 2B). The decreased forward progres-
sion was associated with lower directional persistence of migration as 
measured by the confinement ratio between the track displacement and 
the accumulated distance travelled (Fig. 2C). We additionally examined 
the requirement of MICAL1 for directional migration across 2-dimen-
sional (2D) surfaces. MDA MB 231 NTC and MICAL1 KO cell 
monolayers were grown to confluence before scratch wounds were 
created. The ability of cells to migrate into the open wounds was 
monitored over a 36 h period and wound widths measured using an 
Incucyte® S3 Live-Cell Analysis System every 2 h. Consistent with their 
decreased directional random cell migration (Fig. 2B and C), MICAL1 KO 
cells moved more slowly into the scratched wounds (Fig. 2D). These 
observations support the conclusion that MICAL1 has an important role 
in enabling efficient and persistent cell motility. 
To determine if there was a comparable role for MICAL1 in breast 
cancer cell motility, MICAL1 expression was knocked down in BT549 
and SUM149PT triple negative metastatic breast cancer cells using 
Fig. 2. MICAL1 knockout reduces MDA MB 231 cell motility. A. Spider track plots showing single cell trajectories of NTC and MICAL1 KO MDA MB 231 cells from a 
representative experiment. B. Single cell random migration track displacement (μm) and C. confinement ratios for) NTC and MICAL1 KO MDA MB 231 cells. Means 
± SD, n = 125 (NTC), n = 117 (KO1) and n = 103 individual cells from two independent experiments indicated by differing symbol shading. * = p < 0.05, ** = p <
0.01 (two tailed unpaired Student’s t-test relative to NTC condition) D. Two-dimensional scratch wound assay of cells migrating into open wounds over 36 h. The 
areas of initial open wound are highlighted in yellow, and the proportion of cells that migrated into the wound from baseline are highlighted in purple. Scale bar =
400 μm. E. Relative cell densities in previously wounded areas of NTC and MICAL1 KO cells after 36 h. Means ± SEM, n = 4 independent replicates. * = p < 0.05 
(one-way ANOVA with post-hoc Dunnett’s multiple comparisons test relative to NTC condition). 
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small-interfering RNA (siRNA; Fig. 3A and S4). Similar to the effect of 
MICAL1 knockout (Fig. 2), knockdown of MICAL1 significantly 
decreased random cell migration track displacements (Fig. 3B) in both 
cell lines. In addition, MICAL1 knockdown also significantly reduced the 
directional persistence of migration by BT549 cells (Fig. 3B). The low 
confinement ratio for SUM149PT cells is indicative of their relatively 
inability to directionally migrate (Fig. 3C). Nonetheless, MICAL1 
knockdown did have some small effect at reducing their directional 
persistence of migration, albeit not significantly (Fig. 3C). These results 
support a general role for MICAL1 in promoting breast cancer cell 
migration. 
3.4. Changes in gene transcription associated with MICAL1 deletion 
Changes to the actin cytoskeleton may result in altered patterns of 
gene expression due to roles in regulating a variety of transcription 
factors [30], including direct influence on the activity of the 
serum-response factor (SRF) working together with the actin-binding 
myocardin-related transcription factors (MTRF) [31]. In parallel, cyto-
skeleton tension is sensed by the mechanoresponsive YAP/TAZ tran-
scriptional co-activators [32]. There also are numerous transcription 
factors that are responsive to ROS, including Nuclear factor E2 related 
factor (Nrf2) [33], β-catenin [34–36], Forkhead box O (FOXO) family 
members [37,38], Nuclear Factor κB [39] and nuclear factor of activated 
T cells (NFAT) [40]. The transcriptomic responses induced by alter-
ations to the cytoskeleton or changes in ROS levels could result in pro-
grammatic changes in gene sets that are linked with specific biological 
processes. Thus, MICAL1 might have effects on gene expression medi-
ated both via actin-dependent and independent pathways. To assess the 
influence of MICAL1 on transcription regulation, polyA+-enriched RNA 
was isolated from MDA MB 231 MICAL1 KO or NTC cells and subjected 
to RNA sequencing (RNA-seq) analysis as we previously described [25, 
41]. Using cut-offs of greater than 1.5 fold change (FC) and adjusted P 
values (padj) less than 0.05, 749 of the 25032 genes sequenced (3.0 %) 
were found to be expressed at significantly differing levels between NTC 
and MICAL1 KO cells (Fig. 4A). Overall, there were more genes 
expressed at lower levels in MICAL1 KO cells, with 398 genes having 
decreased expression (average = − 5.42 ± 10.3, median = − 2.66 FC for 
KO1; average = − 3.43 ± 6.42, median = − 2.22 FC for KO2; Fig. 4B, red 
dots) and 351 genes with increased expression (average = 2.71 ± 1.67 
FC, median = 2.15 FC for KO1; average = 2.13 ± 0.96, median = 1.81 FC 
for KO2; Fig. 4B, green dots), resulting in an overall significant reduction 
of total gene expression (Fig. 4B). 
To characterize the types of molecular functions influenced by 
MICAL1, Gene Set Enrichment Analysis (GSEA) was performed on the 
RNAseq data [42]. Using false discovery rate (FDR) as a means to rank 
the gene sets least likely to be false positive findings, there were no 
positively enriched gene sets (FDR < 25 %) and one negatively enriched 
gene set from the 1708 Gene Ontology Molecular Function gene sets. 
The negatively enriched gene set was “receptor regulator activity”, 
composed of genes associated with binding to and modulating receptor 
activity such as secreted signalling proteins (Fig. 4C). To characterize 
the global effect of MICAL disruption on transcription factor activity, the 
RNAseq data were compared to the 1133 transcription factor target gene 
sets. There were no transcription factor gene sets positively enriched 
using an FDR <25 % cut-off, and 14 gene sets significantly negatively 
enriched (Supplemental Table 1), indicating that the greatest effect of 
MICAL1 KO was on reducing transcription factor activity, in agreement 
with the significantly greater effect on decreasing gene transcript levels 
(Fig. 4B). 
To determine if the effects on F-actin structures shown in Fig. 1F 
were associated with changes in the expression of SRF-regulated genes, 
we examined the expression patterns in MDA MB 231 NTC and MICAL1 
KO cells of 960 genes previously defined as being transcriptionally 
regulated by SRF [43]. MDA MB 231 cells detectably expressed 819 of 
the 960 SRF-regulated genes (85 %), of which 24 were significantly 
altered in both KO cell lines (2.9 %; Fig. 4D). To validate the observed 
effects on selected SRF-regulated genes identified as being significantly 
decreased in expression by RNAseq analysis, we performed quantitative 
RT-PCR (qPCR) using freshly isolated RNA from NTC and MICAL1 KO 
cells and analyzed the expression of 3 exemplars (RHOB, SDC2, CYR61). 
As shown in Fig. 4E, all 3 genes were confirmed as being expressed at 
significantly reduced levels in MICAL KO cells. 
Fig. 3. MICAL1 knockdown reduces BT549 and SUM149PT breast cancer cell motility. A. Western blot of MICAL1 and GAPDH expression in BT549 and SUM149PT 
cells following transfection with non-targeting control (NTC) or MICAL1 targeted small interfering RNA (siRNA). B. Single cell random migration track displacement 
(μm) for BT549 (left graph) and SUM149PT (right graph). Means ± SD; BT549 n = 70 (NTC) and 63 (siRNA), SUM149PT n = 120 (NTC) and 70 (siRNA), from three 
(BT54) and four (SUM149) independent experiments indicated by differing symbol shading. *** = p < 0.001, * = p < 0.05 (one-way ANOVA with post-hoc Dunnett’s 
multiple comparisons test relative to NTC condition). C. Single cell directional migration persistence as reflected by the confinement ratio of accumulated distance to 
total distance travelled for BT549 (left graph) and SUM149PT (right graph). Means ± SD; BT549 n = 70 (NTC) and 63 (siRNA), SUM149PT n = 120 (NTC) and 70 
(siRNA), from three (BT54) and four (SUM149PT) independent experiments indicated by differing symbol shading. **** = p < 0.0001, ns = not significant (one-way 
ANOVA with post-hoc Dunnett’s multiple comparisons test relative to NTC condition). 
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3.5. MICAL1 promotes cancer growth in vivo 
Disruption of MICAL1 expression in MDA MB 231 cells affected 
several cellular properties, including morphology, cell size, motility and 
gene expression (Figs. 1–4). We next sought to determine if MICAL1 
contributed to the tumorigenic properties of these breast cancer cells in 
an in vivo orthotopic tumour model. MDA MB 231 NTC and MICAL1 KO 
cells were injected as 106 cells suspended in 50 % Matrigel into the 
fourth abdominal mammary fat pads of female CD1-nude mice, then 
tumour dimensions were measured after they became palpable over 86 
subsequent days (Fig. 5A). Tumours formed in 7/8 mice injected with 
NTC cells, and 4 mice were deemed to have reached their experimental 
endpoint and removed from the study in under 50 days due to tumours 
approaching or reaching maximally permitted tumour diameters of 10 
Fig. 4. RNA transcriptomic analysis of MICAL1 KO cells. A. X–Y plot of log2 FC for 351 transcripts expressed ≥1.5 FC and Padj < 0.05 in MICAL1 KO1 and MICAL1 
KO2 cells relative to NTC cells (green dots), and 398 transcripts expressed ≥ 1.5 FC and Padj < 0.05 in NTC relative to MICAL1 KO1 and MICAL1 KO2 cells (red dots). 
Deming regression shown by the dotted line indicates the line of best fit for the two-dimensional dataset. B. Scatter plot of log2 FC for 351 transcripts expressed ≥1.5 
FC and Padj < 0.05 in MICAL1 KO1 and MICAL1 KO2 cells relative to NTC cells (Up; green dots), and 398 transcripts expressed ≥ 1.5 FC and Padj < 0.05 in NTC 
relative to MICAL1 KO1 and MICAL1 KO2 cells (Down; red dots). Means ± SD. **** = p < 0.0001 (two-tailed unpaired Student’s t-test). C. Left panel; Gene set 
enrichment analysis (GSEA) enrichment plot for the gene set with a false discovery rate < 25 %. Right panel; Heat map of z scores for 4 independent replicate RNA 
sequence reads for indicated transcripts from NTC or MICAL1 KO1 and KO2 cells. D. Heat map of z scores for 4 independent replicate RNA sequence reads for 
indicated SRF-regulated transcripts from NTC or MICAL1 KO1 and KO2 cells. E. Validation of SRF gene expression in NTC and MICAL1 KO cells by RT-PCR. For each 
transcript, expression was individually normalized to the levels in NTC cells, which has been depicted as a single grey bar. Means ± SD, n = 4 independent replicates. 
**** = p < 0.0001, *** = p < 0.001, ** = p < 0.01, * = p < 0.05 (one-way ANOVA with post-hoc Dunnett’s multiple comparisons test relative to NTC condition). 
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Fig. 5. MICAL1 KO attenuates MDA MB 231 cell growth in vivo. A. MDA MB 231 NTC and MICAL1 KO cells were injected into the mammary fat pads of 9 week old 
immunocompromised mice. Individual tumour volume (mm3) curves for n = 7 NTC and n = 7 MICAL1 KO tumours are shown up to 86 days post-injection. B. 
Tumour volumes (mm3) at experimental endpoints, either study removal due to tumours reaching maximally permitted size or after 86 days post-injection. Means ±
SD, n = 7. * = p < 0.05 (two-tailed unpaired Student’s t-test). C. Kaplan-Meier curve showing the percentage of tumours removed once they reached maximally 
permitted size endpoint (>10 mm in diameter). N = 7. 
Fig. 6. MICAL1 expression and genomic alter-
ations in human breast cancer. A. Publicly avail-
able microarray data was analyzed using 
Oncomine [45], which revealed significantly 
higher expression in indicated breast cancers 
relative to normal control tissues. MICAL1 
expression was normalized to mean expression in 
normal tissue for each indicated study. Box in-
dicates upper and lower quartiles and median, 
whiskers indicate 5–95 % range with outliers. 
Statistical significance was evaluated by 
two-tailed Mann-Whitney tests, **** = p <
0.0001; *** = p < 0.001; * = p < 0.05 B. 
Kaplan-Meier curves showing the probability of 
progression free survival for 1053 patients with 
invasive breast cancer with no MICAL1 (blue line) 
alterations or 29 patients with MICAL1 amplifi-
cations or mutations (red line). Statistical signif-
icance was evaluated by logrank test. Data from 
the 2018 TCGA pan-cancer atlas survey [50].   
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mm (Fig. 5A). For tumours derived from MICAL KO cells, 7/8 mice also 
formed tumours, none of which neared 10 mm in diameter even after 86 
days (Fig. 5A) Using the formula of tumour volume = ½(length X 
width2) [44] to compare tumour growth, the volumes of NTC tumours 
were significantly greater at experimental endpoints than those grown 
from injected MICAL1 KO cells (Fig. 5B). Furthermore, when survival 
was plotted for MICAL1 KO and NTC tumour bearing mice, there was 
obvious separation between the experimental groups (Fig. 5C). 
Together, these data demonstrate that MICAL1 contributes to cancer cell 
morphology, motility and gene expression in vitro and tumour growth in 
vivo. 
Given the significant role that regulation of actin-myosin cytoskel-
eton dynamics has in cancer invasion and metastasis, we next assessed 
whether MICAL1 alterations were associated with human breast cancer. 
Oncomine [45] analysis of publicly available microarray data provided 
evidence implicating increased MICAL1 expression in multiple breast 
cancers such as medullary breast cancer, invasive ductal carcinoma and 
invasive breast carcinoma [46–49] (Fig. 6A). Furthermore, examining 
The Cancer Genome Atlas (TCGA) pan-cancer survey for MICAL1 genetic 
alterations revealed that invasive breast cancer patients [50] with am-
plifications or mutations had significantly (p = 0.0264) reduced pro-
gression free survival (Fig. 6B). Taken together with the mouse 
xenograft cancer model data, these results indicate that MICAL1 makes 
an important contribution to breast cancer. 
4. Discussion 
MICAL family proteins are FAD binding multi-domain proteins that 
oxidize actin in a NADPH dependent manner [20]. Since their discovery 
~20 years ago, MICAL proteins have been associated with several 
cellular process that are dependent on dynamic actin reorganization, 
such as neuronal development, endocytosis, cell division and abscission 
[51,52]. Initial work in Drosophila demonstrated that F-actin is a sub-
strate for MICAL1, which oxidizes two methionine residues, Met44 and 
Met47, resulting in actin depolymerization [21]. Recent evidence in-
dicates that MICAL1 does not directly sever filamentous actin, but 
weakens the links between actin subunits within polymerized filaments 
through methionine oxidation [21,23] and enhances the interaction 
with actin severing proteins such as cofilin1 [53]. These observations 
support a central and prominent role of MICAL proteins in cytoskeleton 
regulation. 
Mesenchymal transformation of epithelial cells, including changes in 
shape, size, and motility, are prominent features of transformed cancer 
cells [54]. Central to these changes is reorganization of actin filaments 
that contribute to the dynamic generation of mechanical force required 
for cell migration and tumour cell metastasis [6]. As a result, signalling 
mechanisms controlling F-actin polymerization and depolymerization 
machinery play critical roles in cancer via their spatial and temporal 
regulation of the actin cytoskeleton. The cytoskeleton also provides a 
physical scaffold that connects extracellular stimuli with intracellular 
signalling events that promote tumour growth and progression. As a 
consequence, inhibition of proteins that regulate the actin cytoskeleton 
often result in decreased tumour growth and/or spread, as work from 
our laboratory demonstrated for in vivo cancer models using small 
molecule inhibitors of the ROCK [29,55,56], LIMK [56] and MRCK ki-
nases [24,57], as well as inhibition of myosin ATPase activity [56]. 
Much of the historical research on MICAL proteins has focussed on 
their roles in normal cells, such that their roles in cancer are not well 
characterized. To determine how MICAL1 signalling contributed to the 
tumourigenic properties of human breast cancer cells, we used CRISPR/ 
Cas9 to disrupt the MICAL1 gene in MDA MB 231 cells, a triple negative 
metastatic mammary adenocarcinoma cell line [58]. Consistent with a 
direct role in regulating F-actin, MICAL1 KO resulted in alterations to the 
organization of the actin cytoskeleton that were associated with 
increased cell size and reduced cell migration (Figs. 1 and 2). We pre-
viously observed that selection of MDA MB 231 cells for their ability to 
pass through narrow diameter microporous membranes led to the 
isolation of a sub-population with reduced F-actin anisotropy, smaller 
cell size and increased cell motility relative to the starting unselected 
population [27,59]. These observations reinforce the conclusion that 
F-actin organization, cell size and motility are inter-connected, and that 
the consequence of MICAL1 gene disruption resulted in direct effects on 
actin organization that were consequently manifested in changes in cell 
morphology and motility. 
Analysis of gene expression revealed that MICAL1 gene disruption 
resulted in changes in the levels of over 700 genes, with the majority 
being reduced in their expression (Fig. 4). Similar to the previous 
observation that the nuclear-localized homologue MICAL2 influenced 
the expression of SRF/MTRF regulated genes via F-actin depolymer-
ization [60], MICAL1 KO significantly altered the expression of 24 
SRF-regulated genes by at least 1.5-fold (Fig. 4). Given that the majority 
of the changes in expression were for genes not known to be regulated by 
SRF/MTRF, they were most likely influenced by actin-independent 
pathways. One possibility is that the absence of MICAL1 protein 
affected ROS-responsive mechanisms that contribute to transcriptional 
regulation. 
To evaluate the relative importance of MICAL1 for breast cancer 
growth in vivo, control and MICAL1 KO cells were grown as orthotopic 
xenograft tumours in immunocompromised mice (Fig. 5). While the 
tumour take of each experimental group was equivalent, 4/7 NTC 
control tumours grew so rapidly that they reached maximally permitted 
size endpoints in less than 50 days after injection. In contrast, none of 
the 7 MICAL KO tumours approached maximally permitted size, and all 
partially regressed after peaking in size 50–80 days after injection 
(Fig. 5A). Previous studies found that siRNA-mediated knockdown of 
MICAL1 expression in MCF-7 human breast adenocarcinoma cells 
reduced epidermal growth factor (EGF) stimulation of AKT signalling 
[61], and that MICAL1 knockdown in T47D human breast adenocarci-
noma cells reduced basal mitogen-activated protein kinase (MAPK) 
signalling and slowed proliferation, which was attributed to decreased 
expression of Cyclin D1 [62]. Analysis of differences in gene expression 
between control and MICAL1 KO cells revealed the only significant 
negatively enriched gene set as receptor regulator activity (Fig. 4C), 
suggesting that loss of MICAL1 expression may have pleiotropic effects 
on numerous signalling pathways. Attenuated growth factor signalling, 
resulting in decreased activity of important regulators of proliferation 
such as AKT and the MAPK pathway, would be predicted to negatively 
affect proliferation and tumour growth. These effects on growth factor 
activity and cellular signalling are likely due to changes in actin cyto-
skeleton structures that contribute to efficient signalling by acting as 
scaffolds and by promoting receptor trafficking, as well as through 
reduced ROS generation and transcription factor activity. 
Evidence from human breast cancer patients also indicates a poten-
tial contribution of elevated MICAL1 expression and activity, particu-
larly associated with invasive and metastatic properties (Fig. 6A and B). 
Analysis of MICAL1 expression in several studies showed increased 
levels relative to normal mammary tissue (Fig. 6A). The most common 
genomic alteration of the MICAL1 gene is amplification, but the ~4 % 
incidence detected in retrospective studies of metastatic breast cancer 
[63] suggests that additional mechanisms make significant contribu-
tions to the observed increased expression levels, such as epigenetic 
alterations that promote efficient gene transcription. Although the 
incidence of MICAL1 gene amplification is relatively low compared to 
the ~15 % incidence of HER2 amplification that reflects HER2 signalling 
being a major cancer driver [64], the significant adverse effect on the 
progression-free survival of patients with MICAL1 amplification relative 
to those without (Fig. 6B) suggests that MICAL1 does indeed positively 
contribute to breast cancer. 
Additional validation studies will clarify the potential of MICAL1 as a 
bona fide chemotherapeutic target for breast cancer treatment, and will 
help to identify the sub-types most likely to benefit from therapy. MDA 
MB 231 breast cancer cells are a representative of triple-negative 
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invasive ductal adenocarcinoma that accounts for ~15 % of all breast 
cancers and which, have limited treatment options and very poor 
prognosis due to rapid growth and spread [65]. As a result, there is an 
urgent need to identify novel molecular targets that could be the focus of 
drug discovery efforts. Further research will also determine if there are 
additional cancer types and sub-types that are promoted by the actions 
of MICAL1. It also remains to be determined which of the actions of 
MICAL1 on cytoskeleton regulation, or as a source of ROS, make the 
greatest contribution to its tumour promoting actions. In support of the 
latter possibility, the reactive oxygen scavenger n-acetylcysteine has 
been proposed to have therapeutic benefit for the therapy of 
triple-negative breast cancer [66]. An advantage of directly inhibiting 
MICAL1 is that it would block both aspects of its biological activities, 
cytoskeleton regulation and ROS generation, thereby having the greatest 
potential effect. 
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